Portola Pharmaceuticals Inc.'s chief financial officer, Mardi Dier, told BioWorld Today the deal with Healthcare Royalty Partners (HCRP) was "exactly what we planned to do" – add "part two" to the "part one" of nondilutive funding late last year, when the company signed a $50 million loan agreement with longtime partners Bristol-Myers Squibb Co. (BMS) and Pfizer Inc. for more resources to develop factor Xa inhibitor antidote Andexxa (andexanet alfa).